Veracyte stockVCYT
Veracyte trades at $24.00, 60.6% below its 52-week high (Jun 30, 2026). The price is below its 50- and 200-day averages, a downtrend. −43.0% year to date, −47.9% over 12 months (S&P 500 over the same period: +8.8%). Next earnings report: Mar 1, 2027.
- Market pulseVeracyte beats Q3 estimates with EPS $0.51 and revenue $151.8M, grows revenue 15% YoY, unveils $100M buyback
- Market pulseVeracyte resets Decipher growth outlook, issues preliminary 2027 guide for mid-single-digit revenue growth and ~22% adjusted EBITDA margin after Q3 beat
- GlobeNewswireVeracyte Announces Third Quarter 2026 Financial Results
The trigger was the quarterly report: EPS 0% year over year, 24.4% above the estimate.
All moves of the day →Ratings, candles, signals and the screener for VCYT — after you log in
Open the terminalFrequently asked questions about Veracyte
What is the Veracyte stock price?
At the close on Nov 5, 2026: $24.00 (−54.30% on the day). 52-week high: $60.91 on Jun 30, 2026. During the session the price is updated with a 15-minute delay, after the close with the day's final figures.
When does Veracyte report earnings?
The next quarterly report is on Mar 1, 2027. Last quarter, earnings per share changed 0% year over year, revenue +15%.
Does Veracyte pay dividends?
No, Veracyte does not pay dividends.
Where does Veracyte trade and how to buy it?
Ticker VCYT, exchange Nasdaq, listed since 2013. You can buy it through a broker with access to US exchanges.
Should I buy Veracyte now?
We do not give buy or sell advice. Ratings, the detailed chart and signals for VCYT are in the terminal after you log in.